— Why it moved
Why AGEN Stock Spiked and Faded Today — July 13, 2026
An $85M raise to fund a Phase 3 colon-cancer trial popped Agenus 45% in half an hour — then the market remembered a raise is dilution.
What moved AGEN stock
Agenus is an immuno-oncology biotech built around a checkpoint-antibody combo, botensilimab and balstilimab. This morning it disclosed a securities purchase agreement for about $85 million upfront — up to $340 million if warrants are exercised — to fund ROBBIN1, a registrational Phase 3 trial in microsatellite-stable colon cancer. It's discontinuing an earlier late-line study to concentrate on that. The raise was led by Commodore Capital, with RA Capital, TCGX and others alongside.
The mechanics
A financing cuts both ways for a cash-burning biotech: it removes the "can they fund the trial" question, which traders like, but it also prints new shares and warrants, which is dilution. Names with a real short interest — Agenus sits around 15% of float short — tend to pop first on the relief, then give it back as the dilution sinks in.
AGEN by the numbers
The alert window
Stock Pulse flagged AGEN at $6.01 at 9:47 AM. The high — $8.70 — came at 10:23 AM, just 36 minutes later. That was the whole window. If you were watching in real time you had a fast, sharp move and not much time to think about it.
How AGEN's move ended
From that 10:23 peak it bled the entire pop back, closing at $6.12 — up a rounding error, 1.7%, from the alert (though still well up on the day from $3.35). The story is real; the reaction was a dilution-funded relief pop that the market un-did by the close.
The tell: when the catalyst is a capital raise, the first green candle is relief and the rest of the day is the dilution — the fade is usually the honest part.